Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Aug 8, 2023, before the open
10-Q filed Aug 8, 2023, 39 days after period end · 0001193125-23-205535
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$85.80M | -$70.73M | -$61.65M | -$49.02M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$4.69 |
| -$4.14 |
| -$3.72 |
| -$3.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.